Neurotherapeutic applications of nanoparticles in Alzheimer’s disease

Amyloid-β and τ serve antioxidant functions in the aging and Alzheimer brain

Smith, M. A., Casadesús, G., Joseph, J. A., & Perry, G. L. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01021-3 · Cited by 189

Red Wine Ingredient Resveratrol Protects from β-Amyloid Neurotoxicity

Savaskan, E., Olivieri, G., Meier, F., Seifritz, E., Wirz‐Justice, A., & Müller-Spahn, F. (2003) · Gerontology · doi:10.1159/000073766 · Cited by 188

F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease

Nourooz‐Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E., & Halliwell, B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720734.x · Cited by 187

Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution

Dube, A., Ng, K., Nicolazzo, J. A., & Larson, I. C. (2010) · Food Chemistry · doi:10.1016/j.foodchem.2010.03.027 · Cited by 187

Anti-amyloidogenic effects of antioxidants: Implications for the prevention and therapeutics of Alzheimer's disease

Ono, K., Hamaguchi, T., Naiki, H., & Yamada, M. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.002 · Cited by 186

In Situ Blood–Brain Barrier Transport of Nanoparticles

Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000003374.58641.62 · Cited by 182

Amyloid-β: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer’s disease

Kontush, A. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00688-8 · Cited by 178

Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance

Liu, G., Men, P., Harris, P. L. R., Rolston, R. K., Perry, G. L., & Smith, M. A. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.020 · Cited by 177

Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds

Camps, P., Formosa, X., Galdeano, C., Muñoz‐Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badı́a, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 174

Ferulic acid destabilizes preformed β-amyloid fibrils in vitro

Ono, K., Hirohata, M., & Yamada, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.148 · Cited by 172

Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology

Hoozemans, J. J. M., Veerhuis, R., Rozemüller, A. J. M., & Eikelenboom, P. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.001 · Cited by 171

Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease

Poirier, J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.003 · Cited by 170

Green tea catechins as a BACE1 (β-Secretase) inhibitor

Jeon, S.-Y., Bae, K., Seong, Y.-H., & Song, K. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.018 · Cited by 168

Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Aβ) of Alzheimer's disease

Syme, C. D., & Viles, J. H. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.09.012 · Cited by 167

The Anti-Amyloidogenic Effect Is Exerted against Alzheimer's β-Amyloid Fibrils in Vitro by Preferential and Reversible Binding of Flavonoids to the Amyloid Fibril Structure

Hirohata, M., Hasegawa, K., Tsutsumi, S., Ohhashi, Y., Ookoshi, T., Ono, K., Yamada, M., & Naiki, H. (2007) · Biochemistry · doi:10.1021/bi061540x · Cited by 167

Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3

Koh, S., Kim, S. H., Kwon, H., Park, Y., Kim, K. S., Song, C. W., Kim, J., Kim, M., Yu, H., Henkel-Tigges, J., et al. (2003) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.07.003 · Cited by 167

Abnormal localization of iron regulatory protein in Alzheimer’s disease

Smith, M. A., Wehr, K., Harris, P. L. R., Siedlak, S. L., Connor, J. R., & Perry, G. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00002-x · Cited by 162

Quinoline‐n‐butylcyanoacrylate‐based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease

Kulkarni, P. V., Roney, C. A., Antich, P. P., Bonte, F. J., Raghu, A. V., & Aminabhavi, T. M. (2009) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.59 · Cited by 161

Natural antioxidants in Alzheimer's disease

Mancuso, C., Bates, T. E., Butterfield, D. A., Calafato, S., Cornelius, C., LORENZO, A. D., Dinkova‐Kostova, A. T., & Calabrese, V. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1921 · Cited by 161

Nanoparticle and other metal chelation therapeutics in Alzheimer disease

Liu, G., Garrett, M. R., Men, P., Zhu, X., Perry, G. L., & Smith, M. A. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.06.006 · Cited by 160

Pyrrolidine Dithiocarbamate Activates Akt and Improves Spatial Learning in APP/PS1 Mice without Affecting β-Amyloid Burden

Malm, T., Iivonen, H., Goldsteins, G., Keksa-Goldsteine, V., Ahtoniemi, T., Kanninen, K. M., Salminen, A., Auriola, S. O. K., van Groen, T., Tanila, H., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0059-07.2007 · Cited by 157

Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias

Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151

Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits

Walsh, T. J., Herzog, C. D., Gandhi, C. C., Stackman, R. W., & Wiley, R. G. (1996) · Brain Research · doi:10.1016/0006-8993(96)00271-5 · Cited by 151

ApoE3 Mediated Poly(butyl) Cyanoacrylate Nanoparticles Containing Curcumin: Study of Enhanced Activity of Curcumin against Beta Amyloid Induced Cytotoxicity Using In Vitro Cell Culture Model

Mulik, R. S., Mönkkönen, J., Juvonen, R. O., Mahadik, K. R., & Paradkar, A. R. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900306x · Cited by 150

Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β

Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149

Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice

Schüssel, K., Schäfer, S., Bayer, T. A., Czech, C., Pradier, L., Müller-Spahn, F., Müller, W. E., & Eckert, A. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.003 · Cited by 149

Effects of CDP-Choline Treatment on Neurobehavioral Deficits after TBI and on Hippocampal and Neocortical Acetlycholine Release

Dixon, C. E., Ma, X., & Marion, D. W. (1997) · Journal of Neurotrauma · doi:10.1089/neu.1997.14.161 · Cited by 148

Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease

Liu, G., Men, P., Kudo, W., Perry, G., & Smith, M. A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.064 · Cited by 148

Neuroprotective Effects of Resveratrol against Intracerebroventricular Colchicine-Induced Cognitive Impairment and Oxidative Stress in Rats

Kumar, A., Naidu, P. S., Seghal, N., & Padi, S. S. V. (2006) · Pharmacology · doi:10.1159/000097511 · Cited by 147

Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells

Gómez‐Ramos, A., Díaz‐Nido, J., Smith, M. A., Perry, G. L., & Ávila, J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10525 · Cited by 146

Oxidative Stress Induces Increase in Intracellular Amyloid β-Protein Production and Selective Activation of βI and βII PKCs in NT2 Cells

Paola, D., Domenicotti, C., Nitti, M., Vitali, A., Borghi, R., Cottalasso, D., Zaccheo, D., Odetti, P. R., Strocchi, P., Marinari, U. M., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2756 · Cited by 146

Oxidative Stress Induces Increase in Intracellular Amyloid β-Protein Production and Selective Activation of βI and βII PKCs in NT2 Cells

Paola, D., Domenicotti, C., Nitti, M., Vitali, A., Borghi, R., Cottalasso, D., Zaccheo, D., Odetti, P. R., Strocchi, P., Marinari, U. M., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2164 · Cited by 145

Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?

Amenta, F., Parnetti, L., Gallai, V., & Wallin, A. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00310-4 · Cited by 145

Curcumin, the active constituent of turmeric, inhibits amyloid peptide‐induced cytochemokine gene expression and CCR5‐mediated chemotaxis of THP‐1 monocytes by modulating early growth response‐1 transcription factor

Giri, R. K., Rajagopal, V., & Kalra, V. K. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02800.x · Cited by 144

Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent

Beffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142

Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery

Jain, S., Gupta, Y., Jain, A., Saxena, A. R., Khare, P., & Jain, A. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2007.11.004 · Cited by 142

Neuroprotective effects of (−)‐epigallocatechin gallate after hypoxia‐ischemia‐induced brain damage: novel mechanisms of action

Sutherland, B. A., Shaw, O. M., Clarkson, A. N., Jackson, D. M., Sammut, I. A., & Appleton, I. (2004) · The FASEB Journal · doi:10.1096/fj.04-2806fje · Cited by 140

Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system

Friese, A. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00073-9 · Cited by 139

Green tea catechins prevent cognitive deficits caused by Aβ1–40 in rats

Haque, A. M., Hashimoto, M., Katakura, M., Hara, Y., & Shido, O. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2007.08.008 · Cited by 139

Effect of tramiprosate in patients with mild-to-moderate alzheimer's disease: Exploratory analyses of the MRI sub-group of the alphase study

Gauthier, S. G., Aisen, P. S. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., Garceau, D., Suhy, J., Oh, J., Lau, W. C., et al. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0106-x · Cited by 136

Histochemically Reactive Zinc in Plaques of the Swedish Mutant β-Amyloid Precursor Protein Transgenic Mice

Lee, J., Mook‐Jung, I., & Koh, J. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-11-j0002.1999 · Cited by 136

Short Amyloid-β (Aβ) Immunogens Reduce Cerebral Aβ Load and Learning Deficits in an Alzheimer's Disease Mouse Model in the Absence of an Aβ-Specific Cellular Immune Response

Maier, M., Seabrook, T. J., Lazo, N. D., Jiang, L., Das, P., Janus, C., & Lemere, C. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0381-06.2006 · Cited by 135

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Eriksen, J. L., Sagi, S. A., Smith, T. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318162 · Cited by 135

Protection by EGb 761 against β-amyloid-induced neurotoxicity: Involvement of NF-κB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation

Longpré, F., Garneau, P., Christen, Y., & Ramassamy, C. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.08.015 · Cited by 132

Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro

Hirohata, M., Ono, K., Naiki, H., & Yamada, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.004 · Cited by 132

Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence

Kivipelto, M., & Solomon, A. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00685.x · Cited by 132

Choline Alphoscerate in Cognitive Decline and in Acute Cerebrovascular Disease: An Analysis of Published Clinical Data

Parnetti, L., Amenta, F., & Gallai, V. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00312-8 · Cited by 132

Incorporation of basic fibroblast growth factor into methylpyrrolidinone chitosan fleeces and determination of the in vitro release characteristics

Berscht, P. C., Nies, B. A., Liebendörfer, A., & Kreuter, J. (1994) · Biomaterials · doi:10.1016/0142-9612(94)90209-7 · Cited by 131

Potential of Nanoparticulate Drug Delivery Systems by Intranasal Administration

Ali, J., Ali, M., Baboota, S., Sahni, J. K., Ramassamy, C., Dao, L. H., & Bhavna (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791164108 · Cited by 130

Galantamine Enhances Dopaminergic Neurotransmission In Vivo Via Allosteric Potentiation of Nicotinic Acetylcholine Receptors

Schilström, B., Ivanov, V., Wiker, C., & Svensson, T. H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301087 · Cited by 128

Selective blockade of dopamine D3versus D2receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis

Millan, M. J., Cara, B. D., Dekeyne, A., Panayi, F., de Groote, L., Sicard, D., Cistarelli, L., Billiras, R., & Gobert, A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04262.x · Cited by 126

Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS

Ma, Q., Li, Y., Du, J., Liu, H., Kanazawa, K., Nemoto, T., Nakanishi, H., & Zhao, Y. (2006) · Peptides · doi:10.1016/j.peptides.2005.09.002 · Cited by 123

Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?

Parnetti, L., Mignini, F., Tomassoni, D., Traini, E., & Amenta, F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.043 · Cited by 122

Hippocampal acetylcholine release correlates with spatial learning performance in freely moving rats

Fadda, F., Cocco, S., & Stancampiano, R. (2000) · Neuroreport · doi:10.1097/00001756-200007140-00040 · Cited by 122

Cholinesterase Inhibitors Stabilize Alzheimer's Disease

Giacobini, E. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06942.x · Cited by 122

Nordihydroguaiaretic acid potently breaks down pre‐formed Alzheimer's β‐amyloid fibrils in vitro

Ono, K., Hasegawa, K., Yoshiike, Y., Takashima, A., Yamada, M., & Naiki, H. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00904.x · Cited by 121

Lecithin for dementia and cognitive impairment

Higgins, J. P. T., & Flicker, L. A. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001015 · Cited by 117

Control of brain endothelial permeability.

Nj, A., & Pa, R. (1991) · PubMed · Cited by 117

Nicotine breaks down preformed Alzheimer’s β-amyloid fibrils in vitro

Ono, K., Hasegawa, K., Yamada, M., & Naiki, H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01417-8 · Cited by 116

Epigallocatechin-3-gallate suppresses NF-κB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells

Kim, S.-J., Jeong, H.-J., Lee, K.-M., Myung, N.-Y., An, N.-H., Mo Yang, W., Kyu Park, S., Lee, H.-J., Hong, S.-H., Kim, H.-M., et al. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.11.001 · Cited by 116

Contribution of Presystemic Hepatic Extraction to the Low Oral Bioavailability of Green Tea Catechins in Rats

Cai, Y., Anavy, N. D., & Chow, H. ‐. S. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1246 · Cited by 115

Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal level

Nilsson, L. M., Nordberg, A. K., Hardy, J., Wester, P. O., & Winblad, B. G. (1986) · Journal of Neural Transmission · doi:10.1007/bf01243353 · Cited by 114

Human amyloid β‐induced neuroinflammation is an early event in neurodegeneration

Craft, J. M., Watterson, D. M., & Eldik, L. J. V. (2005) · Glia · doi:10.1002/glia.20306 · Cited by 111

Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models

Sonnen, J. A., Breitner, J. C. S., Lovell, M. A., Markesbery, W. R., Quinn, J. F., & Montine, T. J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.04.022 · Cited by 107

Inhibition of ??-Secretase as a Therapeutic Intervention for Alzheimer???s Disease

Evin, G. M., Sernee, M. F., & Masters, C. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00002 · Cited by 106

Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?

Ramassamy, C., Longpré, F., & Christen, Y. (2007) · Current Alzheimer Research · doi:10.2174/156720507781077304 · Cited by 106

Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

Agyare, E. K., Curran, G. L., Ramakrishnan, M., Yu, C. C., Poduslo, J. F., & Kandimalla, K. K. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9688-y · Cited by 104

Nasal Aβ Treatment Induces Anti‐Aβ Antibody Production and Decreases Cerebral Amyloid Burden in PD‐APP Mice

Lemere, C. A., Maron, R., SPOONER, E. T., Grenfell, T. J., Mori, C., Desai, R. V., Hancock, W. W., Weiner, H. L., & Selkoe, D. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06943.x · Cited by 101

Co-localization of vasoactive intestinal polypeptide, $γ$-aminobutyric acid and choline acetyltransferase in neocortical interneurons of the adult rat

Bayraktar, T., Staiger, J. F., Acsady, L., Cozzari, C., Freund, T. F., & Zilles, K. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00218-7 · Cited by 99

Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease

Nam, D. T., Arseneault, M., Murthy, V., & Ramassamy, C. (2010) · Current Molecular Pharmacology · doi:10.2174/1874-470211003020066 · Cited by 97

Amyloid-Beta Associated with Chitosan Nano-Carrier has Favorable Immunogenicity and Permeates the BBB

Songjiang, Z., & Wu, L. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9279-1 · Cited by 94

Microspheres and drug therapy : pharmaceutical, immunological, and medical aspects

Davis, S. S. (1984) · Medical Entomology and Zoology · Cited by 92

In Vivo and in Vitro Assessment of Baseline Blood-Brain Barrier Parameters in the Presence of Novel Nanoparticles

Lockman, P. R., Koziara, J. M., Roder, K. E., Paulson, J. R., Abbruscato, T. J., Mumper, R. J., & Allen, D. D. (2003) · Pharmaceutical Research · doi:10.1023/a:1023492015851 · Cited by 92

Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-β fibrils detection and removal by a magnetic field

Skaat, H., & Margel, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.110 · Cited by 92

A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease

Portelius, E., Dean, R. A., Gustavsson, M. K., Andréasson, U., Zetterberg, H., Siemers, E., & Blennow, K. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt30 · Cited by 92

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years

Bullock, R. M., & Dengiz, A. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00562.x · Cited by 87

Vasoactive intestinal peptide protects against β‐amyloid‐induced neurodegeneration by inhibiting microglia activation at multiple levels

Delgado, M., Varela, N., & González‐Rey, E. (2008) · Glia · doi:10.1002/glia.20681 · Cited by 87

Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?

Castellani, R., Smith, M. A., Nunomura, A., Harris, P., & Perry, G. (1999) · Free Radical Biology & Medicine · doi:10.1016/s0891-5849(99)00016-7 · Cited by 87

Methionine regulates copper/hydrogen peroxide oxidation products of Aβ

Ali, F. E. A., Separovic, F., Barrow, C. J., Cherny, R. A., Fraser, F. W., Bush, A. I., Masters, C. L., & Barnham, K. J. (2004) · Journal of Peptide Science · doi:10.1002/psc.626 · Cited by 87

Copper (II) modulates in vitro aggregation of a tau peptide

Zhou, L., Du, J., Zeng, Z., Wu, W., Zhao, Y., Kanazawa, K., Ishizuka, Y., Nemoto, T., Nakanishi, H., & Li, Y. (2007) · Peptides · doi:10.1016/j.peptides.2007.08.022 · Cited by 87

Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau

Santa‐María, I., Hernández, F., Rio, J. D., Moreno, F. J., & Ávila, J. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-17 · Cited by 86

EGCG functions through estrogen receptor‐mediated activation of ADAM10 in the promotion of non‐amyloidogenic processing of APP

Fernandez, J. W., Rezai-Zadeh, K. P., Obregon, D. F., & Tan, J. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.09.022 · Cited by 86

Memantine

McKeage, K. (2009) · CNS Drugs · doi:10.2165/11201020-000000000-00000 · Cited by 85

Protective properties of melatonin-loaded nanoparticles against lipid peroxidation

Schaffazick, S. R., Pohlmann, A. R., de Cordova, C. A. S., Creczynski‐Pasa, T. B., & Guterres, S. S. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.003 · Cited by 84

Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease

Hamaguchi, T., Ono, K., & Yamada, M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5599-9 · Cited by 83

Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease

Bodor, N. S., & Buchwald, P. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02332-2 · Cited by 83

Estrogen and Hippocampal Plasticity in Rodent Models

Foy, M., Baudry, M., Brinton, R., & Thompson, R. F. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15406 · Cited by 81

Protective effects of green tea catechins on cerebral ischemic damage.

Suzuki, M., Tabuchi, M., Ikeda, M., Umegaki, K., & Tomita, T. (2004) · PubMed · Cited by 79

L-α-glycerylphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat

Sigala, S., Impérato, A., Rizzonelli, P., Casolini, P., Missale, C., & Spano, P. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90392-h · Cited by 79

Functional Convergence of Dopaminergic and Cholinergic Input Is Critical for Hippocampus-Dependent Working Memory

Wisman, L. A. B., Şahin, G., Maingay, M., Leanza, G., & Kirik, D. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1885-08.2008 · Cited by 77

Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease

Nam, D. T., Arseneault, M., Murthy, V., et al. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003020066 · Cited by 77

Nanoneuroscience: Emerging Concepts on Nanoneurotoxicity and Nanoneuroprotection

Sharma, H. S. (2007) · Nanomedicine · doi:10.2217/17435889.2.6.753 · Cited by 75

A Novel Signaling Molecule for Neuropeptide Action: Activity‐dependent Neuroprotective Protein

Gozes, I., Bassan, M., Zamostiano, R., Pinhasov, A., Davidson, A., Giladi, E., Perl, O., Glazner, G. W., & Brenneman, D. E. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07884.x · Cited by 70

The Scopolamine-Induced Impairment of Spatial Cognition Parallels the Acetylcholine Release in the Ventral Hippocampus in Rats

Mishima, K., Iwasaki, K., Tsukikawa, H., Matsumoto, Y., Egashira, N., Abe, K., Egawa, T., & Fujiwara, M. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.84.163 · Cited by 67

APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease

Barabash, A., Marcos, A., Ancín, I., Vázquez-Álvarez, B., de Ugarte, C., Gil, P., Fernández, C., Encinas, M., López-Ibor, J. J., & Cabranes, J. A. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.003 · Cited by 66

Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-β-peptide aggregation

Santa‐María, I., Hernández, F., Moreno, F. J., & Ávila, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.068 · Cited by 65

Functional reconstitution of γ‐secretase through coordinated expression of presenilin, nicastrin, Aph‐1, and Pen‐2

Periz, G., & Fortini, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20203 · Cited by 65

Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply

Atwood, C., Bowen, R. L., Smith, M. A., & Perry, G. L. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00206-6 · Cited by 64

Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver

Schaffazick, S. R., Siqueira, I. R., Badejo, A. S., Jornada, D. S., Pohlmann, A. R., Netto, C. A., & Guterres, S. S. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.11.010 · Cited by 64

Polyphenol-induced dissociation of various amyloid fibrils results in a methionine-independent formation of ROS

Shoval, H., Weiner, L. M., Gazit, E., Levy, M., Pinchuk, I., & Lichtenberg, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.08.007 · Cited by 63

HRT and cognitive decline

Maki, P. M., & Hogervorst, E. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(02)00082-9 · Cited by 63

The Early and Ongoing Experience with the Cholesterol-Fed Rabbit as a Model of Alzheimer's Disease: The Old, the New and the Pilot

Sparks, D. L. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15410 · Cited by 62

Plasma appearance and correlation between coffee and green tea metabolites in human subjects

Renouf, M., Guy, P. A., Marmet, C., Longet, K., Fraering, A.-L., Moulin, J., Barron, D., Dionisi, F., Cavin, C., Steiling, H., et al. (2010) · British Journal Of Nutrition · doi:10.1017/s0007114510002709 · Cited by 62

Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity

Pierrot, N., & Jean-Noël, O. (2008) · Current Alzheimer Research · doi:10.2174/156720508783954721 · Cited by 60

Thioflavins released from nanoparticles target fibrillar amyloid β in the hippocampus of APP/PS1 transgenic mice

Siegemund, T., Paulke, B. ‐., Schmiedel, H., Bordag, N., Hoffmann, A. H., Harkany, T., Tanila, H., Kacza, J., & Härtig, W. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.012 · Cited by 60

Preformed β-amyloid fibrils are destabilized by coenzyme Q10 in vitro

Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.132 · Cited by 59

β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons

Beffert, U., Aumont, N., Dea, D., Lussier‐Cacan, S., Davignon, J., & Poirier, J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041458.x · Cited by 59

Living with the enemy: a physiological role for the β-amyloid peptide

Esteban, J. A. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.10.008 · Cited by 59

The inhibitory effects of different curcuminoids on β-amyloid protein, β-amyloid precursor protein and β-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells

Liu, H., Li, Z., Qiu, D., Gu, Q., Lei, Q., & Li, M. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.08.035 · Cited by 59

Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's disease

Härtig, W., Paulke, B., Varga, C., Seeger, J., Harkany, T., & Kacza, J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01399-x · Cited by 58

Nanoparticulate devices for brain drug delivery

Celia, C., Cosco, D., Paolino, D., & Fresta, M. (2010) · Medicinal Research Reviews · doi:10.1002/med.20201 · Cited by 58

The Integrated Role of Desferrioxamine and Phenserine Targeted to an Iron‐Responsive Element in the APP‐mRNA 5′‐Untranslated Region

Venti, A., Giordano, T., Eder, P. S., Bush, A. I., Lahiri, D. K., Greig, N. H., & Rogers, J. T. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.003 · Cited by 58

Melatonin ameliorates Alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin A

Yang, X., Yang, Y., Fu, Z., Li, Y., Feng, J. B., Luo, J., Zhang, Q., Wang, Q., & Tian, Q. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110367723 · Cited by 57

The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ

Ono, K., Naiki, H., & Yamada, M. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778793010 · Cited by 57

Delivering Peptides to the Central Nervous System: Dilemmas and Strategies

Banks, W. A., Kastin, A. J., & Barrera, C. M. (1991) · Pharmaceutical Research · doi:10.1023/a:1015884603456 · Cited by 54

Modulation of Blood-Brain Barrier Permeability

Rapoport, S. I. (1996) · Journal of drug targeting · doi:10.3109/10611869609015962 · Cited by 54

Relative tolerability of Alzheimer's disease treatments.

Alva, G., & Cummings, J. L. (2008) · Europe PMC (PubMed Central) · Cited by 53

Reversal of amyloid β toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid β antibody

Chauhan, N. B., & Siegel, G. J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10286 · Cited by 53

CHOLESTEROL TRANSPORT AND SYNTHESIS IN SPORADIC ALZHEIMER'S DISEASE

Poirier, J., & Apolipoprotein, E. (2005) · Cited by 52

Targeted brain delivery of 17β-estradiol via nasally administered water soluble prodrugs

Al-Ghananeem, A. M., Traboulsi, A. A., Dittert, L. W., & HUSSAIN, A. A. (2002) · AAPS PharmSciTech · doi:10.1208/pt030105 · Cited by 51

Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neurotransmission

Fontana, D. J., Inouye, G. T., & Johnson, R. M. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90267-4 · Cited by 47

A gorge-spanning, high-affinity cholinesterase inhibitor to explore β-amyloid plaques

Elsinghorst, P. W., Härtig, W., Goldhammer, S., Grosche, J., & Gütschow, M. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b909612d · Cited by 47

A Phase 2 Study of Tramiprosate for Cerebral Amyloid Angiopathy

Greenberg, S. M., Rosand, J. M., Schneider, A. T., Pettigrew, L. C., Gandy, S., Rovner, B. W., Fitzsimmons, B., Smith, E. E., Gurol, M. E., Schwab, K. M., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213845.28624.f4 · Cited by 46

Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's β-amyloid fibrils in vitro

Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.11.001 · Cited by 45

Estrogen has anti-amyloidogenic effects on Alzheimer’s β-amyloid fibrils in vitro

Morinaga, A., Hirohata, M., Ono, K., & Yamada, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.158 · Cited by 44

Gold nanoparticles for selective and remote heating of β-amyloid protein aggregates

Bastús, N. G., Kogan, M. J., Amigo, R., Grillo‐Bosch, D., Araya, E., Turiel, A., Labarta, A., Giralt, E., & Puntes, V. (2006) · Materials Science and Engineering C · doi:10.1016/j.msec.2006.08.003 · Cited by 43

Absorption, tissue distribution and excretion of radiolabelled compounds in rats after administration of [14C]-l-α-glycerylphosphorylcholine

Abbiati, G., Fossati, T., Lachmann, G., Bergamaschi, M., & Castiglioni, C. (1993) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03188793 · Cited by 40

VIP Neurotrophism in the Central Nervous System: Multiple Effectors and Identification of a Femtomolar‐Acting Neuroprotective Peptide

Brenneman, D. E., Glazner, G. W., Hill, J. M., Hauser, J. M., Davidson, A., & Gozes, I. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb11180.x · Cited by 39

Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease

Bassil, N., Thaipisuttikul, P., & Grossberg, G. T. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.493874 · Cited by 38

The Functions of the Amyloid Precursor Protein Gene

Panegyres, P. K. (2001) · Reviews in the Neurosciences · doi:10.1515/revneuro.2001.12.1.1 · Cited by 36

Assay To Screen for Molecules That Associate with Alzheimer's Related β-Amyloid Fibrils

Inbar, P., Bautista, M. R., Takayama, S. A., & Yang, J. (2008) · Analytical Chemistry · doi:10.1021/ac702592f · Cited by 35

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The Alzhemedtm (Tramiprosate) experience

Saumier, D., Aisen, P. S. S., Gauthier, S. G., Vellas, B. J., Ferris, S. H., Duong, A., Suhy, J., Oh, J., Lau, W. C., Garceau, D., et al. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0047-4 · Cited by 34

γ-Secretase as a Therapeutic Target in Alzheimers Disease

Guardia‐Laguarta, C., Pera, M., & Lleó, A. (2010) · Current Drug Targets · doi:10.2174/138945010790980349 · Cited by 33

Therapeutic Perspectives in Alzheimers Disease

Tschäpe, J., & Hartmann, T. (2006) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488906775245354 · Cited by 28

Cholinesterase Inhibitor Use in U.S. Nursing Homes: Results from the National Nursing Home Survey

Seitz, D. P., Gruneir, A., Conn, D. K., & Rochon, P. A. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02552.x · Cited by 27

5‐HT1A receptors are involved in the effects of xaliproden on G‐protein activation, neurotransmitter release and nociception

Martel, J.-C., Assié, M. B., Bardin, L., Depoortère, R., Cussac, D., & Newman‐Tancredi, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00249.x · Cited by 27

In vivo labelling of hippocampal β‐amyloid in triple‐transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles

Härtig, W., Kacza, J., Paulke, B., Grosche, J., Bauer, U. U. I., Hoffmann, A., Elsinghorst, P. W., & Gütschow, M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.07038.x · Cited by 26

Differential changes in rat cholinergic parameters subsequent to immunotoxic lesion of the basal forebrain nuclei

Waite, J. J., & Chen, A. D. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02968-7 · Cited by 25

Neuroprotective effects of estradiol-17β: implications for psychiatric disorders

Kölsch, H., & Rao, M. L. (2002) · Archives of Women s Mental Health · doi:10.1007/s00737-002-0005-1 · Cited by 22

A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers.

Gatti, G., Barzaghi, N., Acuto, G., Abbiati, G., Fossati, T., & Perucca, E. (1992) · PubMed · Cited by 22

What we have learned from the xaliproden Sanofi-aventis trials

Douillet, P., & Orgogozo, J. M. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0045-6 · Cited by 20

Combination treatments in Alzheimer’s disease: risks and benefits

Sobów, T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.43 · Cited by 20

Effect of Sucrose on Formation of the .BETA.-Amyloid Fibrils and D-Aspartic Acids in A.BETA.1-42.

Ueda, T., Nagata, M., Monji, A., Yoshida, I., Tashiro, N., & Imoto, T. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.375 · Cited by 20

Current State of Immunotherapy for Alzheimer’s Disease

Relkin, N. R. (2008) · CNS Spectrums · doi:10.1017/s1092852900027061 · Cited by 14

Alzheimer's disease and melatonin

Matsubara, E., Shoji, M., Murakami, T., Kawarabayashi, T., & Abe, K. (2003) · International Congress Series · doi:10.1016/s0531-5131(03)00019-0 · Cited by 12

Gastrointestinal Adverse Events in a General Population Sample of Nursing Home Residents Taking Cholinesterase Inhibitors

Hughes, A., Musher, J., Thomas, S. K., Beusterien, K. M., Strunk, B., & Arcona, S. (2004) · The Consultant Pharmacist · doi:10.4140/tcp.n.2004.713 · Cited by 12

Penicillamine: Pharmacokinetics and Differential Effects on Zinc and Copper Status in Chicks

Lü, J., & Combs, G. F. (1992) · Journal of Nutrition · doi:10.1093/jn/122.2.355 · Cited by 10

Phenserine Axonyx.

Thatte, U. M. (2005) · PubMed · Cited by 9

Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil

Fillit, H. M. (2010) · Evidence-Based Mental Health · doi:10.1136/ebmh1069 · Cited by 7

Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial

Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5

Untitled work

(2000) · doi:10.1002/1531-8249(200011)48:5

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630

Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier

Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 544

Bioavailability enhancers of herbal origin: An overview

Kesarwani, K., & Gupta, R. (2013) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(13)60060-x · Cited by 499

Nanoparticles in Drug Delivery: From History to Therapeutic Applications

Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., et al. (2022) · Nanomaterials · doi:10.3390/nano12244494 · Cited by 468

Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting

Fazil, M., Md, S., Haque, S., Kumar, M., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.013 · Cited by 379

The Delivery Challenge in Neurodegenerative Disorders: The Nanoparticles Role in Alzheimer’s Disease Therapeutics and Diagnostics

de la Torre, C., & Ceña, V. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040190 · Cited by 42

Advanced Nanoparticular Approaches to Combat Alzheimer's Disease

Shah, R. K., & Bhattacharya, S. (2021) · Pharmaceutical Nanotechnology · doi:10.2174/2211738509666211123091913 · Cited by 3

Applications of Nanoparticles in Alzheimer’s Disease

Liu, Y., & Shen, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230098 · Cited by 12

Advances in developing therapeutic strategies for Alzheimer's disease

Nguyen, T. T., Nguyen, T. T. D., Nguyen, T. K. O., Vo, T. K., & Giau, V. V. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111623 · Cited by 108

Keyword index

(1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90051-5